Abstract
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention.
Keywords: Alzheimer’s disease, cognitive decline, dementia, protection, vascular risk factors.
CNS & Neurological Disorders - Drug Targets
Title:Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
Volume: 14 Issue: 2
Author(s): Apostolos Safouris, Theodora Psaltopoulou, Theodoros N. Sergentanis, Eleni Boutati, Elisabeth Kapaki and Georgios Tsivgoulis
Affiliation:
Keywords: Alzheimer’s disease, cognitive decline, dementia, protection, vascular risk factors.
Abstract: Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention.
Export Options
About this article
Cite this article as:
Safouris Apostolos, Psaltopoulou Theodora, Sergentanis N. Theodoros, Boutati Eleni, Kapaki Elisabeth and Tsivgoulis Georgios, Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?, CNS & Neurological Disorders - Drug Targets 2015; 14 (2) . https://dx.doi.org/10.2174/1871527314666150217123147
DOI https://dx.doi.org/10.2174/1871527314666150217123147 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bidirectional Nature of Cardiovascular and Kidney Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mean Platelet Volume During Ischemic Stroke is a Potential Pro-inflammatory Biomarker in the Acute Phase and During Neurorehabilitation Not Directly Linked to Clinical Outcome
Current Neurovascular Research The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research Adaptive Behavior in Williams-Beuren Syndrome, Down Syndrome, and Autism Spectrum Disorder
Current Psychiatry Reviews Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Synthesis and Evaluation of Substituted 4-methyl-2-oxo-2H-chromen-7-yl Phenyl Carbamates as Potent Acetylcholinesterase Inhibitors and Anti- Amnestic Agents
Medicinal Chemistry Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research